AOD-9604 5mg

Buy high-purity AOD-9604 in Australia (5mg). Third-party lab tested at >99% purity. Australian-domestic shipping, AUD pricing, supplied for laboratory research use only.

About AOD-9604

AOD-9604 is a synthetic 16-amino-acid peptide corresponding to the C-terminal fragment (residues 177–191) of human growth hormone, modified with an additional N-terminal tyrosine residue to improve stability. Originally developed at Monash University as part of research into the lipolytic domain of hGH, AOD-9604 retains many of the fat-mobilising characteristics of full-length growth hormone while lacking the broader growth-promoting and insulin-resistance effects associated with the parent molecule. It is widely used as a research probe for adipose-tissue lipolysis and metabolic regulation.

Optic Labs supplies AOD-9604 as a lyophilised research-grade peptide for laboratories investigating adipocyte lipolysis, β3-adrenergic signalling, and energy-balance pathways. Each vial is third-party HPLC verified at >99% purity. AOD-9604 peptide is supplied for laboratory research use only and is not intended for human consumption, cosmetic application, or any therapeutic purpose.

Product specifications

• Compound: AOD-9604 (hGH 177–191 fragment, Tyr-modified)
• CAS number: 221231-10-3
• Molecular formula: C₇₈H₁₂₃N₂₃O₂₃S₂
• Molecular weight: ~1815.1 g/mol
• Sequence: Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (with disulfide bridge)
• Form: Lyophilised powder
• Purity: >99% by HPLC
• Available sizes: 5mg vial
• Storage: 2–8°C, protect from light. Reconstituted: 2–8°C, used within 30 days.
• Origin: Manufactured to research-grade specifications, third-party HPLC verified
• Shipping: Australia-wide domestic dispatch from Sydney, NSW

Research background

AOD-9604 originated from research at Monash University in the 1990s seeking to isolate the lipolytic domain of human growth hormone from its growth-promoting and metabolic-side-effect domains. The 177–191 fragment was identified as the lipolytic active site, and a tyrosine residue was added at the N-terminus to enhance stability. Since then, AOD-9604 has appeared across many lines of preclinical and early-phase clinical research focused on obesity, adipose biology, and articular cartilage models.

• Adipocyte lipolysis — published in vitro studies have characterised AOD-9604's stimulation of lipolysis in isolated rat and human adipocytes.
• Diet-induced obesity models — animal-model research has explored AOD-9604's effect on body composition, fat-mass markers, and energy expenditure in rodent obesity models.
• β3-adrenergic and lipolytic-pathway research — laboratory work has examined the receptor-independent and β3-adrenergic-related signalling associated with AOD-9604.
• Insulin and glucose handling — preclinical investigation has tracked changes in fasting glucose, insulin sensitivity, and hepatic glucose output, distinguishing AOD-9604 from intact hGH.
• Cartilage and osteoarthritis models — published research has explored AOD-9604 in articular cartilage and chondrocyte models, sometimes in combination with HA or other matrix peptides.
• Adipose-tissue gene expression — laboratory studies have profiled changes in genes associated with lipolysis, β-oxidation and adipogenesis following AOD-9604 exposure.
• Comparative GH-fragment research — AOD-9604 is frequently used as a comparator alongside other GH-related peptides to characterise the lipolytic-only profile.

For a more detailed research summary, see our AOD-9604 fat loss research guide and our AOD-9604 vs Retatrutide comparison. Researchers working with reconstitution should also reference our peptide reconstitution guide.

Reconstitution and handling

AOD-9604 is supplied as a lyophilised powder and is reconstituted prior to use with sterile bacteriostatic water. A common laboratory approach is to add 1 mL of bac water to a 5mg vial, yielding a 5 mg/mL working concentration; at this concentration, 0.1 mL drawn into an insulin syringe corresponds to 500 µg of peptide. Reconstituted AOD-9604 should be stored at 2–8°C, protected from light, and used within 30 days. For step-by-step dilution mathematics, see our reconstitution calculator guide and our peptide storage research guide.

Commonly stacked research peptides

In published metabolic and body-composition research, AOD-9604 is frequently grouped with other peptides investigated for energy-expenditure, GH-axis and adipose research:

• Retatrutide — GLP-1/GIP/glucagon triple agonist often compared to AOD-9604 in body-composition research.
• CJC-1295 + Ipamorelin — GH-axis stack referenced alongside AOD-9604 in growth-hormone-pathway research.
• Tesamorelin — GHRH 1–44 analogue investigated for visceral-adipose research alongside AOD-9604.
• MOTS-c — mitochondrial-derived peptide cross-referenced in metabolic-rate research.
• 5-Amino-1MQ — NNMT inhibitor investigated in adipose energy-expenditure research alongside AOD-9604.

For more on multi-peptide research designs, see our peptide research stacks overview.

Frequently asked questions

Is AOD-9604 legal in Australia?

AOD-9604 is supplied by Optic Labs strictly for laboratory research, development and analytical use. It is not approved by the Therapeutic Goods Administration for human therapeutic use and is not a registered medicine. For a detailed overview of Australian peptide research regulation, see our guide to peptide legality and TGA compliance in Australia.

What is AOD-9604?

AOD-9604 is a synthetic 16-amino-acid peptide corresponding to the C-terminal lipolytic fragment of human growth hormone (residues 177–191), with an N-terminal tyrosine added for stability. It is studied in laboratory research as a probe for adipose-tissue lipolysis, distinct from full-length hGH. See our AOD-9604 research guide for a deeper overview.

How does AOD-9604 differ from full-length hGH in research models?

Published research characterises AOD-9604 as retaining the lipolytic domain of hGH while lacking measurable activity at the GH receptor — animal-model studies have therefore reported lipolytic effects without the IGF-1, insulin-resistance or growth-promoting changes associated with intact growth hormone.

How is AOD-9604 supplied?

Optic Labs supplies AOD-9604 as a lyophilised powder in glass research vials, available in 5mg. Each vial is sealed and shipped with a tamper-evident seal. Certificates of analysis showing HPLC purity testing are available on request.

How much bacteriostatic water do I mix with an AOD-9604 5mg vial?

A common laboratory dilution is 1 mL of bacteriostatic water per 5mg vial, giving a 5 mg/mL solution. The exact volume depends on your research protocol — see our reconstitution calculator guide for dilution mathematics.

How should reconstituted AOD-9604 be stored?

Reconstituted AOD-9604 should be kept at 2–8°C, protected from light, and used within 30 days. Long-term storage of unreconstituted lyophilised powder should be at −20°C or colder. See our peptide storage complete research guide for handling detail.

Where does Optic Labs ship to?

Optic Labs ships Australia-wide from Sydney, NSW. Standard dispatch is next business day on orders received before the daily cut-off. International shipping is not currently offered.

Legal disclaimer

All products on this site are supplied for laboratory research, development or analytical use only. They are not for human consumption, clinical use, or any diagnostic, cosmetic or veterinary application. These products and statements have not been evaluated by the Therapeutic Goods Administration (TGA) or the APVMA and are not intended to diagnose, treat, cure or prevent any disease. Optic Labs is not a compounding pharmacy or manufacturing facility as defined under the Therapeutic Goods Act 1989, and is not a registered provider of scheduled medicines or therapeutic goods.